The consumption of omega-3 polyunsaturated fatty acids improves clinical outcomes and prognosis in pancreatic cancer patients: A systematic evaluation

Nutrition and Cancer

Volumn 67, Issue 1, 2015, Pages 112-118

  Ma, Ying Jie ^a   Yu, Jing ^a   Xiao, Jing ^a   Cao, Bang Wei ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

OMEGA 3 FATTY ACID;

ARTICLE; BODY MASS; BODY WEIGHT; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; DIET SUPPLEMENTATION; FAT INTAKE; HUMAN; LEAN BODY WEIGHT; LIPID DIET; META ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTING ENERGY EXPENDITURE; STEATORRHEA; SURVIVAL TIME; SYSTEMATIC REVIEW; WEIGHT CHANGE; ADVERSE EFFECTS; BASAL METABOLIC RATE; CACHEXIA; DIET THERAPY; METABOLISM; MULTIMODALITY CANCER THERAPY; PANCREATIC NEOPLASMS; PARANEOPLASTIC SYNDROMES; PROGNOSIS;

BASAL METABOLISM; CACHEXIA; COMBINED MODALITY THERAPY; FATTY ACIDS, OMEGA-3; FOOD, FORTIFIED; HUMANS; PANCREATIC NEOPLASMS; PARANEOPLASTIC SYNDROMES; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84920510795     PISSN: 01635581     EISSN: 15327914     Source Type: Journal    
DOI: 10.1080/01635581.2015.976315     Document Type: Article

References (31)

1. Barber MD, Ross JA, Voss AC, Tisdale MJ, and Fearon KC: The effect of an oral nutritional supplement enriched with fish oil on weight-loss in patients with pancreatic cancer. Br J Cancer 81, 80-86, 1999.
2. American Cancer Society: Cancer Facts & Figures 2013. Atlanta: American Cancer Society, 2013.
3. Bauer J, Capra S, Battistutta D, Davidson W, Ash S, et al.: Compliance with nutrition prescription improves outcomes in patients with unresectable pancreatic cancer. Clin Nutr 24, 998-1004, 2005.
4. Moses AW, Slater C, Preston T, Barber MD, and Fearon KC: Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids. Br J Cancer 90, 996-1002, 2004.
5. Barber MD, Preston T, McMillan DC, Slater C, Ross JA, et al.: Modulation of the liver export protein synthetic response to feeding by an n-3 fatty-Acid-enriched nutritional supplement is associated with anabolism in cachectic cancer patients. Clin Sci (Lond) 106, 359-364, 2004.
6. Fearon KC, Von Meyenfeldt MF, Moses AG, Van Geenen R, Roy A, et al.: Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial. Gut 52, 1479-1486, 2003.
7. Wigmore SJ, Barber MD, Ross JA, Tisdale MJ, and Fearon KC: Effect of oral eicosapentaenoic acid on weight loss in patients with pancreatic cancer. Nutr Cancer 36, 177-184, 2000.
8. Barber MD, Fearon KC, Tisdale MJ, McMillan DC, and Ross JA: Effect of a fish oil-enriched nutritional supplement on metabolic mediators in patients with pancreatic cancer cachexia. Nutr Cancer 40, 118-124, 2001.
9. Wigmore SJ, Ross JA, Falconer JS, Plester CE, Tisdale MJ, et al.: The effect of polyunsaturated fatty acids on the progress of cachexia in patients with pancreatic cancer. Nutrition 12, S27-S30, 1996.
10. Mantovani G, Maccio A, Madeddu C, Serpe R, Massa E, et al.: Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia. Oncologist 15, 200-211, 2010.
11. Barber MD, McMillan DC, Preston T, Ross JA, and Fearon KC: Metabolic response to feeding in weight-losing pancreatic cancer patients and its modulation by a fish-oil-enriched nutritional supplement. Clin Sci (Lond) 98, 389-399, 2000.
12. Zuijdgeest-Van Leeuwen SD, Dagnelie PC, Wattimena JL, Van den Berg JW, Van der Gaast A, et al.: Eicosapentaenoic acid ethyl ester supplementation in cachectic cancer patients and healthy subjects: Effects on lipolysis and lipid oxidation. Clin Nutr 19, 417-423, 2000.
13. Seyfried TN and Shelton LM: Cancer as a metabolic disease. Nutr Metab (Lond) 7, 7, 2010.
14. Barber MD, Ross JA, Preston T, Shenkin A, and Fearon KC: Fish oilenriched nutritional supplement attenuates progression of the acute-phase response in weight-losing patients with advanced pancreatic cancer. J Nutr 129, 1120-1125, 1999.
15. Macasek J, Vecka M, Zak A, Urbanek M, Krechler T, et al.: Plasma fatty acid composition in patients with pancreatic cancer: correlations to clinical parameters. Nutr Cancer 64, 946-955, 2012.
16. Bao Y, Ng K, Wolpin BM, Michaud DS, Giovannucci E, et al.: Predicted vitamin D status and pancreatic cancer risk in two prospective cohort studies. Br J Cancer 102, 1422-1427, 2010.
17. Barber MD and Fearon KC. Tolerance and incorporation of a high-dose eicosapentaenoic acid diester emulsion by patients with pancreatic cancer cachexia. Lipids 36, 347-351, 2001.
18. Davidson W, Ash S, Capra S, Bauer J, and Cancer Cachexia Study Group: Weight stabilisation is associated with improved survival duration and quality of life in unresectable pancreatic cancer. Clin Nutr 23, 239-247, 2004.
19. Fearon KC, Barber MD, Moses AG, Ahmedzai SH, Taylor GS, et al.: Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia. J Clin Oncol 24, 3401-3407, 2006.
20. McQuellon RP, Moose DB, Russell GB, Case LD, Greven K, et al.: Supportive use of megestrol acetate (Megace) with head/neck and lung cancer patients receiving radiation therapy. Int J Radiat Oncol Biol Phys 52, 1180-1185, 2002.
21. Seyfried TN, Flores RE, Poff AM, and D'Agostino DP: Cancer as a metabolic disease: implications for novel therapeutics. Carcinogenesis 35, 515-527, 2014.
22. Murphy RA, Wilke MS, Perrine M, Pawlowicz M, Mourtzakis M, et al.: Loss of adipose tissue and plasma phospholipids: relationship to survival in advanced cancer patients. Clin Nutr 29, 482-487, 2010.
23. Stratton RJ and Elia M: A critical, systematic analysis of the use of oral nutritional supplements in the community. Clin Nutr 18, S29-S84, 1999.
24. Sultan J, Griffin SM, Di Franco F, Kirby JA, Shenton BK, et al.: Randomized clinical trial of omega-3 fatty acid-supplemented enteral nutrition versus standard enteral nutrition in patients undergoing oesophagogastric cancer surgery. Br J Surg 99, 346-355, 2012.
25. Caglayan K, Oner I, Gunerhan Y, Ata P, Koksal N, et al.: The impact of preoperative immunonutrition and other nutrition models on tumor infiltrative lymphocytes in colorectal cancer patients. Am J Surg 204, 416-421, 2012.
26. Maruyama T, Mimura K, Izawa S, Shiba S, Watanabe M, et al.: Immunonutritional diet modulates natural killer cell activation and Th17 cell distribution in patients with gastric and esophageal cancer. Nutrition 27, 146-152, 2011.
27. Arshad A, Chung WY, Isherwood J, Mann CD, Al-Leswas D, et al.: Cellular and plasma uptake of parenteral omega-3 rich lipid emulsion fatty acids in patients with advanced pancreatic cancer. Clin Nutr 2013.
28. Berquin IM, Edwards IJ, and Chen YQ: Multi-Targeted therapy of cancer by omega-3 fatty acids. Cancer Lett 269, 363-377, 2008.
29. Cerchietti LC, Navigante AH, and Castro MA: Effects of eicosapentaenoic and docosahexaenoic n-3 fatty acids from fish oil and preferential Cox-2 inhibition on systemic syndromes in patients with advanced lung cancer. Nutr Cancer 59, 14-20, 2007.
30. Ramos EJ, Middleton FA, Laviano A, Sato T, Romanova I, et al.: Effects of omega-3 fatty acid supplementation on tumor-bearing rats. J Am Coll Surg 199, 716-723, 2004.
31. Bruera E, Strasser F, Palmer JL, Willey J, Calder K, et al.: Effect of fish oil on appetite and other symptoms in patients with advanced cancer and anorexia/cachexia: A double-blind, placebo-controlled study. J Clin Oncol 21, 129-134, 2003.